Could Roche’s Top-Selling Drug Be Harming Women with Primary Progressive Multiple Sclerosis?
The US Food and Drug Administration (FDA) is currently reassessing the approval of Roche’s flagship drug, ocrelizumab (marketed as Ocrevus), specifically for its use in...
















